Medivir AB has posted results from its Phase I study of cathepsin K inhibitor MIV-711 for the treatment of osteoarthritis and other bone related disorders. The seven-day trial data included the following findings: Serum levels of the bone resorption marker CTX-I were suppressed in a dose-dependent manner with up to 55% at 24 hours post last dose on Day 7 Urinary excretion of the cartilage degradation marker CTX-II was reduced in a dose-dependent manner with up to 72% post last dose on D...